patent.fyi
Applications  /  US 2026/0355194
United States Patent Application Publication

US 2026/0355194 A1

Published
Nov 12, 2026
Filed
Aug 9, 2023
Earliest date on the face
Dec 6, 2022
Classification
A61K 31/506
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Thioether linker between fragments

What ifWhat if a thioether sulfur joins the two fragments at X?
Claim language“O, NH, S(O)2, C(O) or —(CH2)n—”

A divalent sulfur atom forms a single bond to each fragment. The two bent carbon–sulfur bonds and their longer bond lengths set the spacing and orientation between the fragments.

1.2Three carbon methylene bridge

What ifWhat if the methylene bridge contains three repeating units?
Claim language“0, or 1, or 2”

Three consecutive methylene groups connect the two attachment points. Rotation about the two internal carbon–carbon bonds lets the bridge adopt extended and folded conformations.

1.3Sulfur in a fused ring

What ifWhat if a five-membered thiophene ring places sulfur at the position corresponding to A?
Claim language“selected from C or N”

The thiophene ring shares two adjacent carbon atoms with the neighboring ring and places sulfur at a nonfusion position. A sulfur lone pair contributes two electrons to the six-electron aromatic system of the five-membered ring.

1.4Carbon linked primary carboxamide

What ifWhat if a primary carboxamide occupies the R1 position and attaches through its carbonyl carbon?
Claim language“C4-C8 heterocyclyl or —NR4R5”

The scaffold bonds directly to the carbonyl carbon of a –C(O)NH2 group. The carbonyl oxygen accepts hydrogen bonds, and the amide N–H bonds donate them.

1.8Methylamino group at R6

What ifWhat if a methylamino group occupies R6 in the –C(O)R6 group?
Claim language“C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl or C6-C10 aryl”

The methylamino nitrogen bonds directly to the carbonyl carbon and forms a secondary amide, –C(O)NHCH3. The carbonyl oxygen accepts hydrogen bonds, and the N–H bond donates one.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Biochemical screening for veterinary oncology research

A benzothiazole pyrimidineamine inhibitor serves as a reference compound in a veterinary oncology research assay. Purified canine DYRK2, a peptide substrate, and adenosine triphosphate occupy each reaction well. The assay measures peptide phosphorylation across a dilution series and normalizes the results to wells containing the same solvent concentration.

Component substitution

Sulfoxide linker in the inhibitor scaffold

A sulfoxide group, S(O), replaces the S(O)2 linker between the same two attachment points in a benzothiazole pyrimidineamine scaffold. The corresponding thioether supplies the sulfur linkage, and controlled oxidation introduces one oxygen atom on sulfur. Liquid chromatography coupled to mass spectrometry distinguishes the sulfoxide from residual thioether and sulfone, and a chiral column separates the sulfur stereoisomers for individual DYRK2 assays.

Parameter or scale variation

Ten point assay in 384 wells

A 384-well plate holds 20 µL reactions containing purified DYRK2, a peptide substrate, adenosine triphosphate, and a benzothiazole pyrimidineamine inhibitor. The inhibitor is dispensed in duplicate at ten concentrations in a threefold dilution series starting at 30 µM, with 0.5% dimethyl sulfoxide in every well. The assay measures adenosine diphosphate after 30 minutes at 25 °C and normalizes the signal against solvent-only and enzyme-free controls.

Combination with existing systems

Continuous perfusion of tumor spheroids

A microfluidic perfusion chip holds tumor spheroids in recessed chambers connected to a shared outlet. Separate pumps deliver culture medium and medium containing a benzothiazole pyrimidineamine inhibitor, and a junction mixes the streams upstream of the chambers. The pump ratio sets the inhibitor concentration at fixed total flow, and time-lapse microscopy measures spheroid area during exposure and washout.

Direct binding measurement by surface plasmon resonance

A surface plasmon resonance flow cell carries purified DYRK2 immobilized on a sensor surface and a reference channel with the same surface chemistry. The instrument injects a concentration series of the benzothiazole pyrimidineamine inhibitor through both channels, then switches to compound-free buffer to record dissociation. Reference-channel subtraction and solvent correction yield binding responses for an equilibrium affinity fit.

Automated or data-driven variant

Automated selection of follow up concentrations

A liquid handler dispenses benzothiazole pyrimidineamine inhibitor dilutions into wells containing DYRK2 reaction reagents, and a plate reader sends the resulting signals to analysis software. The software normalizes the signals to control wells and fits a four-parameter concentration-response curve. When the measurements bracket half-maximal inhibition, the software generates a second plate map with concentrations spaced twofold around the fitted midpoint.

Specific version of a part

Sulfonyl linker between fragments

The X position contains a sulfonyl group with two sulfur–oxygen double bonds and one sulfur–carbon bond to each fragment. The two oxygen atoms provide hydrogen-bond acceptor sites.

Methyl and cyclopropyl substituents

The R1 amino nitrogen carries methyl at R4 and cyclopropyl at R5. The cyclopropyl group attaches through one of its three ring carbons, and the nitrogen has three carbon bonds.

Methoxy group at R2

An oxygen atom connects the scaffold to a methyl group at R2, forming –OCH3. The ether oxygen serves as a hydrogen-bond acceptor adjacent to the scaffold.

Ethyl ester at R3

The R3 position carries –C(O)OCH2CH3 and attaches to the scaffold through the ester carbonyl carbon. The ester connects the carbonyl carbon to the two-carbon ethyl group through a single oxygen atom.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0170911 A1
Published
Jul 2, 2009
Filed
Feb 20, 2009
Class
A61K 31/4192
Document BUS 2022/0315597 A1
Published
Oct 6, 2022
Filed
Jun 5, 2020
Class
C07D 487/14
Claim 1
Document A
Document B
1.1X is selected from: O, NH, S(O)2, C(O) or —(CH2)n—
1.2n is 0, or 1, or 2
As X in formula III, a substituted or unsubstituted lower alkylene group, a substituted or unsubstituted lower alkenylene group, an oxygen atom, a substituted or unsubstituted amino group, a sulfur atom, and a bond are preferable.
A · US 2009/0170911 A1 · ¶ 254
1.3A, B, C are each independently selected from C or N
1.4R1 is selected from: hydrogen, deuterium, halogen, hydroxy, mercapto, cyano, nitro, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C6-C10 aryl, C5-C10 heteroaryl, C4-C8 heterocyclyl or —NR4R5
As the substituent of the substituted cycloalkyl group, the substituted cycloalkenyl group, the substituted aryl group, the substituted heteroaryl group, and the substituted heterocyclic group in the present invention, for example, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group, a substituted or unsubstituted lower alkynyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylt
A · US 2009/0170911 A1 · ¶ 241
R1 is selected from hydrogen, C1-6 alkyl optionally substituted with one or more deuterium, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-(C3-8 cycloalkyl), —(C1-6 alkyl)-(3-8 membered heterocyclyl), —(C1-6 alkyl)-phenyl, —(C1-6 alkyl)-heteroaryl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, and heteroaryl, wherein each of said C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, and
B · US 2022/0315597 A1 · ¶
1.5wherein R4, R5 are each independently selected from: H, C1-C8 alkyl, C3-C8 cycloalkyl, C6-C10 aryl, C5-C10 heteroaryl or C4-C8 heterocyclyl
is 5 membered heteroaryl containing 1, 2, 3, or 4 ring heteroatoms selected from N, O or S; said 5 membered heteroaryl is optionally substituted with one or more substituents independently selected from deuterium, halo, hydroxy, amino, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —CN, mercapto, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxyl, C1-6 haloalkyl, —(C1-6 alkyl)-OH, and —(C1-6 alkyl)-O—(C1-6 alkyl), wherein each of said C1-6 alkyl, C1-6 alkoxyl, and C1-6 haloalkyl is opti
B · US 2022/0315597 A1 · ¶
1.6R2 is selected from hydrogen, deuterium, hydroxy, mercapto, cyano, halogen, nitro, C3-C8 cycloalkyl, C1-C8 alkyl or C1-C8 alkoxy
R2 is selected from hydrogen, deuterium, halo, hydroxy, amino, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —CN, mercapto, C1-6 alkyl optionally substituted with one or more deuterium, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), —(C1-6 alkyl)-(C3-8 cycloalkyl), —(C1-6 alkyl)-(3-8 membered heterocyclyl), —(C1-6 alkyl)-phenyl, —(C1-6 alkyl)-heteroaryl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl, and heteroaryl, wherein each of said C
B · US 2022/0315597 A1 · ¶
1.7R3 is selected from hydrogen, deuterium, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, —C(O)OC1-C8 alkyl, —C(O)C3-C8 cycloalkyl, C6-C10 aryl, C3-C10 heteroaryl, C4-C8 heterocyclyl or —C(O) R6
Z-Y-X- formula III wherein X is any of an oxygen atom, a substituted or unsubstituted amino group, a sulfur atom, and a bond, Y is any of a carbonyl group, a sulfonyl group, and a bond, and Z is any of a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkanoyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a s
A · US 2009/0170911 A1 · ¶
R3, R4, R5, R6, R7, and R8 are independently selected from hydrogen, deuterium, halo, hydroxy, —CN, mercapto, amino, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, —(C1-6 alkyl)-OH, —(C1-6 alkyl)-O—(C1-6 alkyl), C1-6 alkyl, —(C1-6 alkyl)-phenyl, C1-6 alkoxyl, and C1-6 haloalkyl; or any two of R3, R4, R5, R6, R7, and R8 together with the carbon atom they are attached to and the B ring form a 8-13 membered spirocyclic, fused, or bridged ring optionally containing 1-3 ring heteroatoms indepe
B · US 2022/0315597 A1 · ¶
1.8R6 is selected from C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl or C6-C10 aryl.
Z-Y-X- formula III wherein X is any of an oxygen atom, a substituted or unsubstituted amino group, a sulfur atom, and a bond, Y is any of a carbonyl group, a sulfonyl group, and a bond, and Z is any of a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkanoyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a s
A · US 2009/0170911 A1 · ¶

An empty cell means only that no passage was reproduced there.

Statements in these documents
The compounds of the present invention inhibit the physiological activity of lysophosphatidic acid (LPA), and therefore, are useful as agents for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases in which LDA receptor participates.
A · US 2009/0170911 A1 · ¶ 3
Particularly, the present compounds are useful as agents for the prophylaxis or treatment of fibrosis of organs (liver, kidney, lung, and the like) or liver diseases.
A · US 2009/0170911 A1 · ¶ 3
Accordingly, new compounds and methods for modulating ERK activity and treating related disorders, including cancer, are needed.
B · US 2022/0315597 A1 · ¶ 4
The combination approaches with ERK inhibitors were investigated and the pre-clinical data support the combo strategy with other target inhibitors, such as CDK4/6 inhibitor, VEGFR2 inhibitor, PARP inhibitor, multi-ERBB inhibitor and autophagy inhibitor in KRAS mutant cancer cells.
B · US 2022/0315597 A1 · ¶ 3
Cite aspatent.fyi, US 2026/0355194 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355194/, SHA-256 7764d944f43c52aee808c8b8a459949f99e3d7aaca3ae3324908ceb80902fa52
First published
Permanent addresshttps://patent.fyi/US20260355194/
Content fingerprint (SHA-256)7764d944f43c52aee808c8b8a459949f99e3d7aaca3ae3324908ceb80902fa52
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi